Gyre Therapeutics (GYRE) Share-based Compensation (2010 - 2026)
Gyre Therapeutics (GYRE) posted quarterly Share-based Compensation of $2.6 million for Q1 2026, up 409.47% year-over-year from $507000.0 in Q1 2025, and down 43.81% quarter-over-quarter from $4.6 million in Q4 2025.
Gyre Therapeutics (GYRE) Share-based Compensation (2010 - 2026) Analysis & Trends
Gyre Therapeutics (GYRE) has reported Share-based Compensation for 17 consecutive years, with $2.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Share-based Compensation rose 409.47% year-over-year to $2.6 million; the TTM figure through Mar 2026 stood at $9.2 million (up 232.48% YoY), while the FY2025 annual figure was $18.3 million, up 335.71% from the prior year.
- Share-based Compensation declined to $2.6 million in Q1 2026 per GYRE's latest filing, from $4.6 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $4.6 million in Q4 2025 and bottomed at -$1.0 million in Q4 2022.
- Historically, Share-based Compensation has averaged $726764.7 across 5 years, with a median of $237000.0 in 2024.
- Annual changes were most pronounced in 2022 — Share-based Compensation tumbled 250.51% — and 2025, when it soared 5562.5%.
- Gyre Therapeutics' Share-based Compensation stood at -$1.0 million in 2022, then soared by 88.33% to -$120000.0 in 2023, then soared by 1780.83% to $2.0 million in 2024, then soared by 127.91% to $4.6 million in 2025, then plunged by 43.81% to $2.6 million in 2026.
- Business Quant data shows GYRE's Share-based Compensation at $2.6 million in Q1 2026, $4.6 million in Q4 2025, and $1.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Gyre Therapeutics | 708.31 Mn | 685.47 Mn | 26.90 Mn | 1.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.83 Mn |
| Jun 30, 2026 | 1.83 Mn |
| Mar 31, 2026 | 2.58 Mn |
| Mar 31, 2026 | 2.58 Mn |
| Dec 31, 2025 | 4.60 Mn |
| Dec 31, 2025 | 4.60 Mn |
| Sep 30, 2025 | 1.15 Mn |
| Sep 30, 2025 | 1.15 Mn |
| Jun 30, 2025 | 906,000.00 |
| Jun 30, 2025 | 906,000.00 |
| Mar 31, 2025 | 507,000.00 |
| Mar 31, 2025 | 507,000.00 |
| Dec 31, 2024 | 2.02 Mn |
| Dec 31, 2024 | 2.02 Mn |
| Sep 30, 2024 | 237,000.00 |
| Sep 30, 2024 | 237,000.00 |
| Jun 30, 2024 | 16,000.00 |
| Jun 30, 2024 | 16,000.00 |
| Mar 31, 2024 | 11,000.00 |
| Mar 31, 2024 | 11,000.00 |